366 related articles for article (PubMed ID: 29266235)
1. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy.
Huo YR; Huang Y; Liauw W; Zhao J; Morris DL
Anticancer Res; 2016 Mar; 36(3):1041-9. PubMed ID: 26976996
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis.
Ng JL; Ong WS; Chia CS; Tan GH; Soo KC; Teo MC
Int J Surg Oncol; 2016; 2016():2495131. PubMed ID: 27006828
[TBL] [Abstract][Full Text] [Related]
4. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
6. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Kok NF; Jóźwiak K; Lahaye ML; Beets GL; van Leerdam ME; Boot H; Aalbers AG
Dis Colon Rectum; 2017 May; 60(5):477-487. PubMed ID: 28383447
[TBL] [Abstract][Full Text] [Related]
7. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Bhandare M; Patil P; Pai V; Bhamre R; Engineer R; Ostwal V; Saklani A
Clin Colorectal Cancer; 2017 Jun; 16(2):e1-e6. PubMed ID: 27670895
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM
J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736
[TBL] [Abstract][Full Text] [Related]
11. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
[TBL] [Abstract][Full Text] [Related]
12. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
13. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
15. Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
Paul BK; Ihemelandu C; Sugarbaker PH
Dis Colon Rectum; 2018 Mar; 61(3):347-354. PubMed ID: 29420428
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
17. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Elias D; Mariani A; Cloutier AS; Blot F; Goéré D; Dumont F; Honoré C; Billard V; Dartigues P; Ducreux M
Eur J Surg Oncol; 2014 Nov; 40(11):1467-73. PubMed ID: 25086990
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
19. The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy.
Kozman MA; Fisher OM; Valle SJ; Alzahrani N; Liauw W; Morris DL
Am J Surg; 2020 Jan; 219(1):58-64. PubMed ID: 30982572
[TBL] [Abstract][Full Text] [Related]
20. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]